Manufacturing, latest filing in 2024

Adven Inc. IPO

Adven Inc. filed a Form F-1 registration statement for an initial public offering on 2024-07-12. As of its latest filing, on 2024-07-12, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We will apply to have our Common Shares listed on the NYSE American LLC (“NYSE American”) under the symbol “ADVEN.” This offering is conditional upon the successful listing of our Common Shares on the NYSE American.From the F-1 filed 2024-07-12

For the year ending December 31, 2023, we incurred a net loss of $6.3 million and an operating loss of $3.9 million.From the F-1 filed 2024-07-12

Swipe the table sideways to see every column.

APRINOIA Therapeutics Inc. IPO

APRINOIA Therapeutics Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-28. Amendments on record here: 2. It asked for the registration statement to be withdrawn on 2024-10-28. Each fact below is quoted from the filing named with it.

We have applied for the listing of the ordinary shares on the Nasdaq Global Market (“Nasdaq”), under the symbol “APRI.” There is no assurance that such application will be approved, and if our application is not approved, this offering will not be completed.From the F-1/A filed 2024-09-11

This is an initial public offering of the ordinary shares of APRINOIA Therapeutics Inc. We are offering 500,000 ordinary shares, par value $0.40 per share.From the F-1/A filed 2024-09-11

We expect that the initial public offering price will be between $10.00 and $12.00 per ordinary share.From the F-1/A filed 2024-09-11

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of APN-1607 and APNmAb005, research and development of our degrader therapeutic candidates, other research and development activities as well as for working capital and other general corporate purposes.From the F-1/A filed 2024-09-11

For the years ended December 31, 2023 and 2022, our net losses were $28.6 million and $28.2 million, respectively.From the F-1/A filed 2024-09-11

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “ Securities Act ”), APRINOIA Therapeutics Inc. (the “ Company ”) hereby requests that, effective as of the date first set forth above, the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of the Company’s registration statement on Form F-1 (File No. 333-276696) (together with the exhibits and supplements thereto, the “ Registration Statement ”).From the RW filed 2024-10-28

Swipe the table sideways to see every column.

Artiva Biotherapeutics, Inc. IPO

Artiva Biotherapeutics, Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-15. Amendments on record here: 1. It filed its final prospectus on 2024-07-22, at a public offering price of $12.00 per share. Each fact below is quoted from the filing named with it.

Layoffs on record: about 131 jobs, latest 2026-10-27 (layoff filings and notices).

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Market (Nasdaq) under the symbol “ARTV.”From the 424B4 filed 2024-07-22

We are offering 13,920,000 shares of our common stock.From the 424B4 filed 2024-07-22

The initial public offering price is $12.00 per share of our common stock.From the 424B4 filed 2024-07-22

We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, to (i) fund the clinical development of AlloNK; and (ii) the remainder for additional discovery activities and preclinical development across our pipeline programs, as well as headcount costs, manufacturing and supply activities, working capital and other general corporate purposes.From the 424B4 filed 2024-07-22

For the years ended December 31, 2022 and 2023, our net losses were $58.8 million and $28.7 million, respectively.From the S-1/A filed 2024-07-15

Swipe the table sideways to see every column.

Asep Medical Holdings Inc. IPO

Asep Medical Holdings Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-09. Amendments on record here: 2. As of its latest filing, on 2024-10-04, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list the common shares on The Nasdaq Stock Market LLC under the symbol “SEPS”.From the F-1/A filed 2024-10-04

We intend to use net proceeds from this offering for working capital and general corporate purposes, including product development other than as set forth, we do not anticipate requiring any material amounts of other funds to accomplish the specified purposes.From the F-1/A filed 2024-10-04

The net loss attributable to the shareholders for the year ended December 31, 2023 amounted to $8,227,328 compared to a net loss for the comparative period of $4,524,981 .From the F-1/A filed 2024-10-04

Swipe the table sideways to see every column.

Bicara Therapeutics Inc. IPO

Bicara Therapeutics Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-22. It has amended it 3 times. It filed its final prospectus on 2024-09-13, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 19 records.

Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “BCAX.”From the 424B4 filed 2024-09-13

We are offering 17,500,000 shares of our common stock.From the 424B4 filed 2024-09-13

The initial public offering price is $18.00 per share.From the 424B4 filed 2024-09-13

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, for the following:From the 424B4 filed 2024-09-13

Our net losses totaled $52.0 million and $37.8 million for the years ended December 31, 2023 and 2022, respectively, and $29.6 million and $16.7 million for the six months ended June 30, 2024 and 2023, respectively.From the S-1/A filed 2024-09-11

Swipe the table sideways to see every column.

BioAge Labs, Inc. IPO

BioAge Labs, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-03. It has amended it 2 times. It filed its final prospectus on 2024-09-26, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our common stock on the Nasdaq Global Select Market under the symbol “BIOA.”From the 424B4 filed 2024-09-26

We are offering 11,000,000 shares of our common stock.From the 424B4 filed 2024-09-26

The initial public offering price is $18.00 per share.From the 424B4 filed 2024-09-26

We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents, to advance the continued development of azelaprag for the treatment of obesity in our ongoing STRIDES clinical trial in combination with tirzepatide, a Phase 2 clinical trial in combination with semaglutide, and the manufacture of drug products to support Phase 3 clinical trials sufficient for registration; the initiationFrom the 424B4 filed 2024-09-26

Our net losses were $63.9 million and $39.7 million for the years ended December 31, 2023 and 2022, respectively, and $26.6 million and $28.3 million for the six months ended June 30, 2024 and 2023, respectively.From the S-1/A filed 2024-09-25

Swipe the table sideways to see every column.

Breathe BioMedical Inc. IPO

Breathe BioMedical Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-05. Amendments on record here: 5. It asked for the registration statement to be withdrawn on 2024-10-28. Each fact below is quoted from the filing named with it.

We have applied to list our common shares on the Nasdaq Capital Market under the symbol “BRTH”.From the F-1/A filed 2024-09-30

We expect the initial public offering price to be between $4.00 and $6.00 per share.From the F-1/A filed 2024-09-30

We intend to use the net proceeds from this offering to fund research and development of our product candidates and development programs for working capital and other general corporate purposes and for the repayment of $682,019 in outstanding indebtedness.From the F-1/A filed 2024-09-30

Our net loss was Cdn$8,362,319, Cdn$4,458,293 and Cdn$3,970,833 for the years ended December 31, 2023, 2022 and 2021, respectively.From the F-1/A filed 2024-09-30

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”), Breathe BioMedical Inc. (the “ Company ”) hereby respectfully requests that the U.S. Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Company’s Registration Statement on Form F-1 (File No. 333-280034) together with all exhibits and amendments thereto (collectively, the “ Registration Statement ”) initially filed with the Commission on June 7, 2024 and most recently amended on October 10, 2024.From the RW filed 2024-10-28

Swipe the table sideways to see every column.

Camp4 Therapeutics Corp IPO

Camp4 Therapeutics Corp filed a Form S-1 registration statement for an initial public offering on 2024-09-20. It has amended it 2 times. It filed its final prospectus on 2024-10-11, at a public offering price of $11.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 22 records.

Our common stock has been approved for listing on the Nasdaq Global Market under the trading symbol “CAMP.”From the 424B4 filed 2024-10-11

We are offering 6,820,000 shares of our common stock.From the 424B4 filed 2024-10-11

The initial public offering price is $11.00 per share.From the 424B4 filed 2024-10-11

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:From the 424B4 filed 2024-10-11

For the years ended December 31, 2023 and 2022, we reported net losses of $49.3 million and $44.2 million, respectively.From the S-1/A filed 2024-10-07

Swipe the table sideways to see every column.

Diamond Water Origin Supply Chain Technology Group Co., Ltd. IPO

Diamond Water Origin Supply Chain Technology Group Co., Ltd. filed a Form F-1 registration statement for an initial public offering on 2024-07-03. As of its latest filing, on 2024-07-03, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “ ZSSY ”.From the F-1 filed 2024-07-03

We are offering 930,000 ordinary shares pursuant to this initial public offering.From the F-1 filed 2024-07-03

Swipe the table sideways to see every column.

HUHUTECH International Group Inc. IPO

HUHUTECH International Group Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-28. Amendments on record here: 3. It filed its final prospectus on 2024-10-22, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

Our Ordinary Shares are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “HUHU.”From the 424B4 filed 2024-10-22

We are offering on a firm commitment basis 1,050,000 Ordinary Shares, par value $0.0000025 per share.From the 424B4 filed 2024-10-22

The initial public offering price is $4.00 per Ordinary Share.From the 424B4 filed 2024-10-22

Our total revenue was $16,732,688 and $11,374,257 for the years ended December 31, 2023 and 2022, respectively.From the F-1/A filed 2024-09-09

Swipe the table sideways to see every column.

JBDI Holdings Ltd IPO

JBDI Holdings Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-03. Amendments on record here: 4. As of its latest filing, on 2024-08-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We list our Ordinary Shares on the Nasdaq Capital Market under the symbol “JBDI”.From the F-1/A filed 2024-08-23

We currently intend to use the net proceeds from this offering (i) to improve our automation process, upgrade our infrastructure and to improve our management efficiency in terms of level of technology, automation and precision;From the F-1/A filed 2024-08-23

Our total revenue decreased by approximately $0.8 million or 14.3% to approximately $4.8 million for the six months ended November 30, 2023 from approximately $5.6 million for the six months ended November 30, 2022.From the F-1/A filed 2024-08-23

Our net income amounted to approximately $0.4 million and approximately $0.8 million for the six months ended November 30, 2023 and 2022, respectively.From the F-1/A filed 2024-08-23

Swipe the table sideways to see every column.

JuHe KC Holdings Ltd IPO

JuHe KC Holdings Ltd filed a Form F-1 registration statement for an initial public offering on 2024-12-16. As of its latest filing, on 2024-12-16, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “JHKC”.From the F-1 filed 2024-12-16

Swipe the table sideways to see every column.

Leishen Energy Holding Co., Ltd. IPO

Leishen Energy Holding Co., Ltd. filed a Form F-1 registration statement for an initial public offering on 2024-10-01. It has amended it 2 times. It filed its final prospectus on 2024-12-20, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.

The Ordinary Shares have been approved by The Nasdaq Stock Market LLC (“Nasdaq”) for listing on the Nasdaq Capital Market with the trading symbol “LSE”.From the 424B4 filed 2024-12-20

The initial public offering price is $4.00 per share.From the 424B4 filed 2024-12-20

We plan to use the net proceeds we receive from this offering for the following purposes:From the 424B4 filed 2024-12-20

Swipe the table sideways to see every column.

Leizig Thermal Management Co., Ltd IPO

Leizig Thermal Management Co., Ltd filed a Form F-1 registration statement for an initial public offering on 2024-09-27. As of its latest filing, on 2024-09-27, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We intend to apply to list the Ordinary Shares on the Nasdaq Capital Market under such symbol.From the F-1 filed 2024-09-27

We are offering, on a firm commitment basis, 1,875,000 ordinary shares, par value $0.001 per share (the “Ordinary Shares”) in this Offering pursuant to this Public Offering Prospectus, based on an assumed public offering price of $5.00, the mid-point of the range discussed below.From the F-1 filed 2024-09-27

We expect that the initial public offering price will be between $4.00 and $6.00 per Ordinary Share.From the F-1 filed 2024-09-27

In our endeavors to expand into the international market, we generated revenue of approximately $175,251 from overseas clients for the year ended December 31, 2023.From the F-1 filed 2024-09-27

Swipe the table sideways to see every column.

Li Bang International Corp Inc. IPO

Li Bang International Corp Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-23. Amendments on record here: 2. It filed its final prospectus on 2024-10-22. Each fact below is quoted from the filing named with it.

Our ordinary shares have been approved to list on The Nasdaq Capital Market under the symbol “LBGJ.”From the 424B4 filed 2024-10-22

This is an initial public offering of 1,520,000 ordinary shares of Li Bang International Corporation Inc. (“we”, “our Company”, “Li Bang”, or the “Company”), a Cayman Islands exempted company.From the 424B4 filed 2024-10-22

Swipe the table sideways to see every column.

Mao Shi Jade Jewelry International Investment Ltd. IPO

Mao Shi Jade Jewelry International Investment Ltd. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-24. Amendments on record here: 1. As of its latest filing, on 2024-07-24, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “MSFC”.From the F-1/A filed 2024-07-24

We plan to use the net proceeds we receive from this offering for (i) R&D and patent application of jadeite series products (ii) Jointly build the jadeite alliance public base (iii) Big data center exhibition, partial product processing and sales expansion site construction (iv)Technical system upgrade of the mall(v)Merger and acquisition of jadeite gem mine.From the F-1/A filed 2024-07-24

Swipe the table sideways to see every column.

Upstream Bio, Inc. IPO

Upstream Bio, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-18. It has amended it 1 time. It filed its final prospectus on 2024-10-11, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “UPB.”From the 424B4 filed 2024-10-11

This is an initial public offering of shares of common stock of Upstream Bio, Inc. We are offering 15,000,000 shares of our common stock to be sold in this offering.From the 424B4 filed 2024-10-11

The initial public offering price is $17.00 per share.From the 424B4 filed 2024-10-11

We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments:From the 424B4 filed 2024-10-11

The pro forma net loss attributable to common stockholders used in the calculation of pro forma basic and diluted net loss per share attributable to common stockholders adjusts net loss attributable to common stockholders to remove the cumulative dividends on redeemable convertible preferred stock of $17.7 million and $8.0 million for the year ended December 31, 2023 and six months ended June 30, 2024, respectively.From the S-1/A filed 2024-10-07

Swipe the table sideways to see every column.

Wing Yip Food Holdings Group Ltd IPO

Wing Yip Food Holdings Group Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-25. Amendments on record here: 7. It filed its final prospectus on 2024-11-26. Each fact below is quoted from the filing named with it.

We received the approval letter from The Nasdaq Stock Market LLC (“Nasdaq”) to list the ADSs on the Nasdaq Capital Market under the symbol “WYHG”.From the 424B4 filed 2024-11-26

We are offering a total of 2,050,000 ADSs.From the 424B4 filed 2024-11-26

For the six months ended June 30, 2024, we had total revenue of approximately $68.63 million and net income of approximately $8.88 million.From the F-1/A filed 2024-09-09

For the six months ended June 30, 2024, we had total revenue of approximately $68.63 million and net income of approximately $8.88 million.From the F-1/A filed 2024-09-09

Swipe the table sideways to see every column.

Yuanyi Pharmaceutical Technology Holding Group Co Ltd IPO

Yuanyi Pharmaceutical Technology Holding Group Co Ltd filed a Form F-1 registration statement for an initial public offering on 2024-07-10. As of its latest filing, on 2024-07-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “ ARDH ”.From the F-1 filed 2024-07-10

Swipe the table sideways to see every column.

ZC GOLD Jewelry INC IPO

ZC GOLD Jewelry INC filed a Form S-1 registration statement for an initial public offering on 2024-08-22. As of its latest filing, on 2024-08-22, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our ordinary shares on the Nasdaq Capital Market under the symbol “ ZCXX ”.From the S-1 filed 2024-08-22

We are offering 1,000,000 shares of our Class A common stock.From the S-1 filed 2024-08-22

We currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital and general corporate purposes, including, among other things, capital expenditures.From the S-1 filed 2024-08-22

Swipe the table sideways to see every column.

Zenas BioPharma, Inc. IPO

Zenas BioPharma, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-22. It has amended it 1 time. It filed its final prospectus on 2024-09-13, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

The newest 12 of 18 records.

Our common stock has been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “ZBIO.”From the 424B4 filed 2024-09-13

We are offering 13,235,294 shares of our common stock.From the 424B4 filed 2024-09-13

The initial public offering price is $17.00 per share.From the 424B4 filed 2024-09-13

We currently intend to use the net proceeds from this offering, together with our existing cash, as follows:From the 424B4 filed 2024-09-13

Our net losses for the six months ended June 30, 2024 and 2023 were $65.8 million and $48.1 million, respectively.From the S-1/A filed 2024-09-06

Swipe the table sideways to see every column.

ZJK Industrial Co., Ltd. IPO

ZJK Industrial Co., Ltd. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-07-24. Amendments on record here: 4. It filed its final prospectus on 2024-09-30, at a public offering price of $5.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have received the approval letter from The Nasdaq Stock Market LLC (“Nasdaq”) to have our Ordinary Shares listed on the Nasdaq Capital Market under the symbol “ZJK.”From the 424B4 filed 2024-09-30

The initial public offering price is $5.00 per Ordinary Share.From the 424B4 filed 2024-09-30

We plan to use the net proceeds we receive from this offering for (i) expanding our manufacturing facilities, (ii) expanding sales network in North America, (iii) potential acquisitions of, or investment in, businesses in the field of fasteners, and (iv) general corporate purposes and working capital, including potential strategic investments and acquisitions.From the 424B4 filed 2024-09-30

Swipe the table sideways to see every column.